BAP1 Missense Mutations in Cancer: Friend or Foe?

BRCA-associated protein-1 (BAP1) is mutated in several cancers and a few therapies targeting BAP1 loss-of-function mutations have been proposed, some of them being already tested in clinical trials. However, most of the missense mutations have not been functionally characterized, although such information is essential for successful patient stratification.
(Copyright © 2019 Elsevier Inc. All rights reserved.)